Adamas News

Your Data is Safe With ADAMAS

Your Data is Safe With ADAMAS

Did you know that ADAMAS has made significant investment in compliance with international data privacy and security requirements, in ways that may not be reflected by other smaller organisations or freelancers? For example, all of ADAMAS’s activities are governed by a...

KRIs and QTLs, Simplified

KRIs and QTLs, Simplified

It has been nearly four years since the release of ICH E6 (R2) in November 2016, however a recent poll on status of ICH E6 (R2) showed only 5% of companies as having implemented the addendum, with the top two hurdles being implementation of Risk Based Quality...

Superior Vendor Compliance with ADAMAS

Superior Vendor Compliance with ADAMAS

Did you know that ADAMAS provides an enhanced level of compliance that you may not find when selecting other contract QA organisations or small/solo contractors? ADAMAS has made a significant investment in ‘state of the art’ compliance infrastructure and processes,...

Second Wave, Second Strain

Second Wave, Second Strain

Could a second, potentially more contagious wave, of COVID-19 bring further disruption to travel and clinical trial activities? Is it possible to meet the current oversight and compliance expectations of regulatory authorities? We are all aware of the initial impact...

Do you protect your staff or your Clinical Trial?

Do you protect your staff or your Clinical Trial?

It’s a tough choice – new drugs for patients or the health and safety of your valued staff? With ADAMAS Consulting, you do not have to choose. As we keep hearing these are unprecedented times, and just recently there have been concerning articles in the scientific...

Data Driven Quality Assurance

Data Driven Quality Assurance

“The only constant in life is change”-Heraclitus. This cannot be truer in today’s context. In the past two decades, clinical research industry, has gone through a paradigm shift from the use of paper-based systems to web based electronic systems and from traditional...

COVID-19 | Pharmacovigilance Update

COVID-19 | Pharmacovigilance Update

In response to the COVID-19 pandemic, the Food and Drug Administration (FDA), European Medicine Agency (EMA) and other national health authorities have published guidelines and recommendations regarding post-authorisation Adverse Event (AE) reporting during this...

Archives